This publication does not concern the award of a public contract within the meaning of the Procurement Coordination Directive (2014/24/EU) or antitrust law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1) is due to the specifications of the announcement form. This and the use of the medium “TED” does not involve any submission under procurement regulations whose validity is not mandatory by law or procurement regulations. It is a framework agreement with an option to join, which relates to various active substances.

Medicinal products containing the active substance abirateron are contractual.

The subject of the contract are medicinal products containing the active ingredient nitisinone in the dosage form hard capsules.

The subject of the contract are medicinal products containing the active ingredient nitrofurantoin.

Medicinal products containing the active substance oseltamivir are contractual.

The subject of the contract are medicinal products that contain the active ingredient progesterone in the dosage form vaginal capsules.

The subject of the contract are medicinal products containing the active ingredient combination timolol + latanoprost in the dosage form of single-dose pipettes.

Medicines containing the active substance tranylcypromin are contractual.

Medicines containing the active substance triptorelin embonate are contractual.

The subject of the contract are medicinal products that contain the active ingredient combination aclidinium cation + formoterol.

Medicines containing the active substance aripiprazole in a parenteral dosage form are contractual.

The subject of the contract are medicinal products that contain the active ingredient denosumab in the dosage form pre-filled syringes.

The subject of the contract are medicinal products containing the active ingredient flupentixol in the dosage form solution for injection.

The subject of the contract are medicinal products that contain the active ingredient fluvastatin in the dosage form prolonged-release tablet.

The contract covers medicinal products containing the active ingredient lapatinib (lapatinib).

The subject of the contract are medicinal products that contain the active ingredient methocarbamol with an active potency of 1500 mg and a pack size of 12 pieces.

The subject of the contract are medicinal products containing the active ingredient midazolam hydrochloride in the dosage form pre-filled syringes.